Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221116605
Abstract: Introduction: Despite radical intent therapy for patients with stage III non-small-cell lung cancer (NSCLC), cumulative incidence of brain metastases (BM) reaches 30%. Current risk stratification methods fail to accurately identify these patients. As radiomics features… read more here.
Keywords: development; iii nsclc; stage iii; radically treated ... See more keywords
The Association of Gross Tumor Volume and Its Radiomics Features with Brain Metastases Development in Patients with Radically Treated Stage III Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15113010
Abstract: Simple Summary Around 30% of patients with stage III non-small cell lung cancer (NSCLC) receiving radical chemoradiotherapy will develop symptomatic brain metastases (BM) during the disease course. Identifying risk factors for BM can help improve… read more here.
Keywords: stage iii; radically treated; radiomics features; patients radically ... See more keywords